Leap Therapeutics

About Leap Therapeutics

Leap Therapeutics, Inc. is a biotechnology company focused on developing targeted and immuno-oncology therapeutics with a mission to stop cancer. They aim to understand patient tumor expression and develop new therapies and combinations targeting novel cancer targets.

Products & Services

Sirexatamab (DKN-01):A humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, in development for patients with esophagogastric, gynecologic, and colorectal cancers.

FL-501:A humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, currently in preclinical development.

Specialties

Targeted Therapeutics Immuno-Oncology Monoclonal Antibodies Cancer Research (esophagogastric, gynecologic, colorectal, gastric, pancreatic)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 58888888 MR: - FA: $58.88 million FAN: 58888888	D: 2025-10-09 FD: 2025-10-09	1 investors
2	RT: Private Placement T: - FT: Private Placement	A: 58888888 MR: - FA: 58,888,888 FAN: 58888888	D: 2025-10-06 FD: 2025-10-06	1 investors
3	RT: Private Placement T: - FT: Private Placement	A: 40000000 MR: - FA: $40 million FAN: 40000000	D: 2024-04-11 FD: 2024-04-11	5 investors

Private Placement Latest

2025-10-09

$58.9M

1 investor (Pro only)

Private Placement 2025-10-06

$58.9M

Private Placement 2024-04-11

$40.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Christopher Mirabelli

Chairman of the Board

D

Douglas Onsi

President & CEO

LinkedIn (Pro only)

C

Cyndi Sirard

Chief Medical Officer

LinkedIn (Pro only)

C

Christine Granfield

Vice President, Regulatory and Quality

J

James Cavanaugh

Managing Director at HealthCare Ventures

T

Thomas Dietz

Chairman and CEO of Waypoint Holdings and Managing General Partner at Firebrand River Capital, LLC

View 18 more team members with Pro

Unlock Full Team Directory

Recent News